Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Mol Pharmacol. 2013 Feb;83(2):354-66. doi: 10.1124/mol.112.081794. Epub 2012 Nov 9.
NMDA receptor (NMDAR) antagonists are dissociative anesthetics, drugs of abuse, and are of therapeutic interest in neurodegeneration and neuropsychiatric disease. Many well-known NMDAR antagonists are positively charged, voltage-dependent channel blockers. We recently showed that the hydrophobic anion dipicrylamine (DPA) negatively regulates GABA(A) receptor function by a mechanism indistinguishable from that of sulfated neurosteroids. Because sulfated neurosteroids also modulate NMDARs, here we examined the effects of DPA on NMDAR function. In rat hippocampal neurons DPA inhibited currents gated by 300 µM NMDA with an IC(50) of 2.3 µM. Neither onset nor offset of antagonism exhibited dependence on channel activation but exhibited a noncompetitive profile. DPA antagonism was independent of NMDAR subunit composition and was similar at extrasynaptic and total receptor populations. Surprisingly, similar to cationic channel blockers but unlike sulfated neurosteroids, DPA antagonism was voltage dependent. Onset and offset of DPA antagonism were nearly 10-fold faster than DPA-induced increases in membrane capacitance, suggesting that membrane interactions do not directly explain antagonism. Furthermore, voltage dependence did not derive from association of DPA with a site on NMDARs directly accessible to the outer membrane leaflet, assessed by DPA translocation experiments. Consistent with the expected lack of channel block, DPA antagonism did not interact with permeant ions. Therefore, we speculate that voltage dependence may arise from interactions of DPA with the inherent voltage dependence of channel gating. Overall, we conclude that DPA noncompetitively inhibits NMDA-induced current by a novel voltage-dependent mechanism and represents a new class of anionic NMDAR antagonists.
NMDA 受体(NMDAR)拮抗剂是分离麻醉剂、滥用药物,在神经退行性疾病和神经精神疾病的治疗中具有重要意义。许多著名的 NMDAR 拮抗剂是带正电荷的、电压依赖性通道阻滞剂。我们最近发现,疏水性阴离子二吡咯烷(DPA)通过与硫酸神经甾体相似的机制负调节 GABA(A)受体功能。由于硫酸神经甾体也调节 NMDAR,因此我们在此研究了 DPA 对 NMDAR 功能的影响。在大鼠海马神经元中,DPA 以 2.3µM 的 IC50 抑制 300µM NMDA 门控电流。拮抗剂的起始和结束均不依赖于通道激活,但表现出非竞争性特征。DPA 拮抗作用与 NMDAR 亚基组成无关,在突触外和总受体群体中相似。令人惊讶的是,与阳离子通道阻滞剂相似但与硫酸神经甾体不同,DPA 拮抗作用是电压依赖性的。DPA 拮抗作用的起始和结束比 DPA 诱导的膜电容增加快近 10 倍,这表明膜相互作用不能直接解释拮抗作用。此外,电压依赖性不是由于 DPA 与 NMDAR 上的一个位点结合而产生的,该位点直接可接触到外膜小叶,通过 DPA 易位实验评估。与预期的缺乏通道阻断作用一致,DPA 拮抗作用不与可渗透离子相互作用。因此,我们推测电压依赖性可能源于 DPA 与通道门控的固有电压依赖性的相互作用。总体而言,我们得出结论,DPA 通过一种新的电压依赖性机制非竞争性抑制 NMDA 诱导的电流,代表了一种新的阴离子 NMDAR 拮抗剂。